Want to see OTLK full AI Analyst Report?
Top Page
Outlook Therapeutics
(NASDAQ:OTLK)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.90
▼(-35.79% Downside)
Action:Reiterated
Date:07/30/26
The score is held down primarily by weak financial performance (deep losses, negative gross profit, ongoing cash burn, and negative equity). Technicals are mixed-to-weak with the stock below key short-term moving averages, and valuation metrics are unfavorable/less informative due to losses (negative P/E). These negatives are partially offset by strong corporate-event momentum, led by FDA approval of LYTENAVA and improved listing compliance.
Positive Factors
Regulatory approval for LYTENAVA
FDA approval is a durable structural milestone enabling U.S. commercialization of LYTENAVA. Approval removes a major regulatory obstacle, permits product launch activities and payer engagement, and converts the company from purely development-stage to a potential revenue-generating commercial entity over the coming months.
Negative Factors
Negative shareholder equity / pressured capital structure
Long-standing negative equity indicates accumulated losses have eroded the capital base, weakening balance-sheet resilience. This structural weakness reduces borrowing capacity, heightens refinancing and covenant risk, and increases the likelihood of future dilutive financings if commercial cash flows are insufficient.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory approval for LYTENAVA
FDA approval is a durable structural milestone enabling U.S. commercialization of LYTENAVA. Approval removes a major regulatory obstacle, permits product launch activities and payer engagement, and converts the company from purely development-stage to a potential revenue-generating commercial entity over the coming months.
Read all positive factors
Outlook Therapeutics (OTLK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$141.44M
Dividend YieldN/A
Average Volume (3M)13.68M
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.36
Shares Outstanding186,997,000
10 Day Avg. Volume13,491,520
30 Day Avg. Volume13,678,892
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.15
Price to Sales (P/S)26.09
P/FCF Ratio-0.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.20Price Target Upside271.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$2.87M
Outlook Therapeutics Business Overview & Revenue Model
Company Description
Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010,...
How the Company Makes Money
As a development-stage biopharmaceutical company, Outlook Therapeutics’ ability to generate recurring product revenue depends on obtaining regulatory approvals and successfully commercializing its lead ophthalmology product; specific, consistent c...
Outlook Therapeutics Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Dec 18, 2026
Earnings Call Sentiment Positive
The call conveyed a largely positive tone based on a transformational FDA approval, strong registrational efficacy data, clear commercial planning and recent financing to fund the U.S. launch. However, material risks remain: competitive pricing pressure from biosimilars, European commercialization challenges, reimbursement and patient affordability concerns, reliance on a J‑code and near‑term liquidity that required a public offering. Management positions the company to execute a measured launch with conservative forecasts and contingency upside if compounded bevacizumab availability changes.Positive Updates
FDA Approval of LYTENAVA
FDA approved LYTENAVA as the only FDA‑approved ophthalmic formulation of bevacizumab for wet AMD in the U.S.; management calls this transformational and a foundation for U.S. commercialization.
Negative Updates
Ongoing Competitive and Pricing Pressure
Market dynamics include multiple biosimilar entrants, downward pricing pressure, tenders and alternative therapies (TKIs, IL‑6s, gene therapy) assumed in the model; management explicitly modeled a competitive, price‑pressured environment.
Read all updates
Q3-2026 Updates
Positive
Negative
FDA Approval of LYTENAVA
FDA approved LYTENAVA as the only FDA‑approved ophthalmic formulation of bevacizumab for wet AMD in the U.S.; management calls this transformational and a foundation for U.S. commercialization.
Read all positive updates
Company Guidance
Management's financial and commercial guidance included first‑year U.S. launch net revenues of $50–75 million (with Europe ~10–15% of that), a front‑loaded ramp with ~10% of first‑year revenues in the first 3 months rising to ~50% in the fourth quarter after launch, and an anticipated permanent J‑code in April 2027 (HCPCS application targeted by end of Q3); pricing is planned with WAC below $500 per vial and R&D spend steady over the next 12 months while quarterly SG&A is expected to ~double by end‑2026 and then increase another ~10% during 2027. Operational and market metrics cited include hiring ~30 customer‑facing commercial and ~20 field reimbursement staff, sufficient supply for a late‑2026 launch, cash of $11.2M as of June 30 plus a $55M offering (≈$51.1M net), Q3 adjusted net loss of $10.9M ($0.09/share) versus $15.8M ($0.44), European unit sales +46% QoQ with Q4 units on track to match current, a $500M+ peak U.S. sales target by 2030 (base case) with ~+$300M upside if compounded bev is disrupted, and market context of an ~$8.5B U.S. anti‑VEGF market with ~3.6M repackaged bev injections in 2025 (≈2.2M for wet AMD); clinical data referenced NORSE TWO results (41.7% ≥15‑letter gains at month 11 vs 23.1% for ranibizumab).Outlook Therapeutics Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
6
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 333.14K | 1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.20M | 657.21K | -113.86K | -44.19K | -204.69K | -262.14K |
| EBITDA | -62.08M | -63.58M | -72.09M | -57.38M | -64.36M | -51.51M |
| Net Income | -60.96M | -62.42M | -75.37M | -58.98M | -66.05M | -53.16M |
Balance Sheet | ||||||
| Total Assets | 21.89M | 18.58M | 28.82M | 32.30M | 28.53M | 22.81M |
| Cash, Cash Equivalents and Short-Term Investments | 7.75M | 8.08M | 14.93M | 23.39M | 17.40M | 14.48M |
| Total Debt | 27.19M | 30.19M | 29.74M | 35.56M | 10.96M | 11.90M |
| Total Liabilities | 50.89M | 50.77M | 101.90M | 46.74M | 19.79M | 18.20M |
| Stockholders Equity | -28.99M | -32.19M | -73.08M | -14.44M | 8.74M | 4.61M |
Cash Flow | ||||||
| Free Cash Flow | -47.05M | -51.83M | -68.79M | -42.97M | -56.67M | -54.25M |
| Operating Cash Flow | -47.05M | -51.83M | -68.79M | -42.97M | -56.67M | -54.25M |
| Investing Cash Flow | -3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 47.24M | 44.98M | 60.33M | 48.97M | 59.59M | 56.19M |
Outlook Therapeutics Technical Analysis
Negative
1.40
Price Trends
1.28
Negative
0.80
Negative
0.91
Negative
Market Momentum
-0.10
Positive
34.79
Neutral
39.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OTLK, the sentiment is Negative. The current price of 1.4 is above the 20-day moving average (MA) of 1.09, above the 50-day MA of 1.28, and above the 200-day MA of 0.91, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 34.79 is Neutral, neither overbought nor oversold. The STOCH value of 39.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OTLK.
Outlook Therapeutics Risk Analysis
Outlook Therapeutics disclosed 75 risk factors in its most recent earnings report. Outlook Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Outlook Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
OTLK
Outlook Therapeutics
0.76
-2.01
-72.71%
ALDX
Aldeyra Therapeutics
1.56
-3.88
-71.32%
PRQR
ProQR
1.92
-0.20
-9.43%
Outlook Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Gains FDA Approval for LYTENAVA Launch
Positive
Jul 24, 2026
On July 24, 2026, Outlook Therapeutics announced that the U.S. FDA approved its biologics license application for LYTENAVA, an ophthalmic formulation of bevacizumab for treating neovascular (wet) age-related macular degeneration. The drug becomes ...
Business Operations and StrategyExecutive/Board Changes
Outlook Therapeutics Grants Incentive Awards Tied to FDA Approval
Positive
Jul 24, 2026
On July 21, 2026, Outlook Therapeutics’ compensation committee granted stock options under its 2024 Equity Incentive Plan to Chief Executive Officer Robert C. Jahr and Chief Financial Officer Lawrence A. Kenyon, covering 100,000 and 210,078 ...
Private Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Outlook Therapeutics Shareholders Approve Major Capital Changes
Neutral
Jul 17, 2026
On July 16, 2026, Outlook Therapeutics held a special meeting at which stockholders approved several measures reshaping the company’s capital structure, including an amendment to increase authorized common shares from 260 million to 600 mill...
Delistings and Listing ChangesRegulatory Filings and Compliance
Outlook Therapeutics Regains Nasdaq Minimum Bid Compliance
Positive
Jun 26, 2026
On February 18, 2026, Outlook Therapeutics received a notice from Nasdaq staff that its common stock was subject to delisting from the Nasdaq Capital Market after failing to maintain a minimum bid price of $1.00 per share for 30 consecutive busine...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics’ Resubmitted ONS-5010 BLA Accepted by FDA
Positive
Jun 16, 2026
On June 16, 2026, Outlook Therapeutics announced that the U.S. Food and Drug Administration accepted its resubmitted Biologics License Application for ONS-5010/LYTENAVA (bevacizumab-vikg) as a treatment for neovascular age-related macular degenera...
Product-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Resubmits FDA Application for ONS-5010
Positive
Jun 1, 2026
On June 1, 2026, Outlook Therapeutics announced it had resubmitted its Biologics License Application to the U.S. Food and Drug Administration for ONS-5010/LYTENAVA, an ophthalmic bevacizumab formulation for treating neovascular age-related macular...
Private Placements and FinancingRegulatory Filings and Compliance
Outlook Therapeutics Announces Registered Direct Equity Offering
Positive
May 29, 2026
Outlook Therapeutics, Inc. has entered into a securities purchase agreement dated May 28, 2026, to conduct a registered direct offering of 8,539,709 shares of its common stock to GMS Ventures and Investments. The transaction was executed under the...
Business Operations and StrategyPrivate Placements and Financing
Outlook Therapeutics Announces Insider-Backed Direct Stock Offering
Neutral
May 28, 2026
On May 28, 2026, Outlook Therapeutics, Inc. entered into a securities purchase agreement with GMS Ventures and Investments for a registered direct offering of 8,539,709 shares of common stock at $0.5855 per share, expected to raise approximately $...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Outlook Therapeutics Wins FDA Appeal for LYTENAVA Resubmission
Positive
May 26, 2026
On May 26, 2026, Outlook Therapeutics said the U.S. FDA granted its appeal after a Formal Dispute Resolution process over the December 30, 2025 Complete Response Letter for its ONS-5010/LYTENAVA biologics license application for neovascular age-re...
Business Operations and StrategyPrivate Placements and Financing
Outlook Therapeutics Launches New $100M ATM Offering
Neutral
May 13, 2026
On May 13, 2026, Outlook Therapeutics entered into a new at-the-market offering agreement with H.C. Wainwright Co. that allows the company to issue and sell up to $100 million of its common stock from time to time, with H.C. Wainwright acting as ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.